Review Note
Last Update: 10/07/2024 10:17 PM
Current Deck: Genes and Development::Week 2::LE019 Pharmacogenomics
PublishedCurrently Published Content
Text
childhood acute lymphoblastic leukemia (ALL) is treated with {{c1::6-mercaptopurine (6-MP)}}. 1 in 300 has fatal reaction, 1 in 30 adverse reaction due to genetic variation in {{c2::thiopurine methyl transferase}}.
Low-activity variant {{c3::TPMT decreases}} drug inactivation and leads to high (toxic) levels of thioguanines.
Low-activity variant {{c3::TPMT decreases}} drug inactivation and leads to high (toxic) levels of thioguanines.
Back Extra
Current Tags:
Pending Suggestions
No pending suggestions for this note.